Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1

Status

Recruiting 6Not yet recruiting 3Completed 3Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Plasma cell 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 64Lymphoma 60Lymphoma, Follicular 55Lymphoma, Large B-Cell, Diffuse 52Lymphoma, B-Cell 50Leukemia, Lymphocytic, Chronic, B-Cell 34Lymphoma, Non-Hodgkin 33Recurrence 28Leukemia 22Lymphoma, Mantle-Cell 20Burkitt Lymphoma 20Lymphoma, T-Cell, Peripheral 17Leukemia, Myeloid, Acute 15Hodgkin Disease 15Hematologic Neoplasms 15Waldenstrom Macroglobulinemia 14Lymphoma, B-Cell, Marginal Zone 14Multiple Myeloma 13Lymphoma, T-Cell, Cutaneous 12Lymphoma, Extranodal NK-T-Cell 12Neoplasms 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Leukemia, B-Cell 8Motor Activity 7Myelodysplastic Syndromes 6Mycosis Fungoides 6Sezary Syndrome 5Neoplasm, Residual 5Pain 4Neoplasms, Plasma Cell 4

Interventions

Specimen Handling 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Plasmablastic Lymphoma × Lymphoid × Clear all
NCT07647432 2026-06-15

HEME-25

University of Illinois at Chicago

Phase 2/3 Not yet recruiting
17 enrolled
Lymphoid

Plasmablastic Lymphoma, Acquired Immunodeficiency Syndrome

NCT07332507 2026-05-13

Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
Lymphoid

Plasmablastic Lymphoma

NCT07113496 2025-08-13

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

The First Affiliated Hospital with Nanjing Medical University

Phase 1 Not yet recruiting
27 enrolled
LymphoidPlasma cell

Plasmablastic Lymphoma, Burkitt Lymphoma, Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡